VaramirStart free · no cardSign in
MYGN as of Nov 2 · 10:43 ET
MYGNNasdaqIn Vitro & In Vivo Diagnostic Substances

Myriad Genetics Inc · Brief

Next report

Today

Nov 2 · after closeest.Q3 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
3 of 8≥ implied
avg implied
±26.8%
avg realized
±23.7%
Feb 24 '25±15.7%▼−14.80%×0.94
May 6 '25±30.5%▼−41.27%×1.35
Aug 5 '25±30.6%▲+46.51%×1.52
Nov 3 '25±22.8%▼−21.03%×0.92
Jan 12 '26±12.9%▼−0.15%×0.01
Feb 23 '26±61.3%▲+1.14%×0.02
Q1 FY26±20.1%▼−18.29%×0.91
Q2 FY26±20.0%▼−46.74%×2.34
quarterimplied−65%0+65%realized×
Q2 FY26±20.0%▼−46.74%×2.34
Q1 FY26±20.1%▼−18.29%×0.91
Feb '26±61.3%▲+1.14%×0.02
Jan '26±12.9%▼−0.15%×0.01
Nov '25±22.8%▼−21.03%×0.92
Aug '25±30.6%▲+46.51%×1.52
2 older reports
May '25±30.5%▼−41.27%×1.35
Feb '25±15.7%▼−14.80%×0.94
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 2 report · est.

Bull2 of 4

9disclosed supplier and customer ties in SEC filingsSEC filings
4tracked funds holding MYGNN-PORT · Aug 31 '26

Bear2 of 4

5 of 8recent reports where the move came in under the options-implied rangeEarnings history
8 of 24of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26
AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

MYGN report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 208-KMaterial agreement: Asset Purchase Agreement with Laboratory Corporation of America, a Delaware corporation ("Buyer").Source
Oct 19impliedImplied move: ±22.7% into Nov 2 earnings (Oct 19 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.